Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Ionis Pharmaceuticals (IONS) Stock Price & Analysis
1,240 Followers
IONS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.37 - $54.44
Previous Close$37.31
Volume1.36M
Average Volume (3M)1.11M
Market Cap
$5.45B
Enterprise Value$3.37B
Total Cash (Recent Filing)$2.33B
Total Debt (Recent Filing)$257.04M
Price to Earnings (P/E)-14.0
Beta0.54
Next Earnings
Aug 07, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding145,965,374
10 Day Avg. Volume1,382,464
30 Day Avg. Volume1,106,622
Standard Deviation0.09
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)14.20
Price to Sales (P/S)6.91
Price to Cash Flow (P/CF)41.80
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda-11.02
Forecast
1Y Price Target
$58.25Price Target Upside56.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Corporate Optimism And Pipeline ProgressIonis Pharmaceuticals expresses confidence in advancing ION582 into Phase 3 trials, signaling strong belief in the drug's potential, which is reflected in the analyst's BUY rating and anticipation of multiple clinical catalysts.
Drug Profile And SafetyION582 has shown favorable tolerability, with no reported serious adverse events or lower extremity weakness, highlighting its safety and differentiating it from competitors.
Efficacy And Market OpportunityWith significant improvements in cognitive, communicative, and motor skills observed in patients, ION582 demonstrates strong efficacy, offering a large market opportunity as a potential treatment for Angelman Syndrome.
Bears Say
Clinical Trial Results44% triglyceride reduction is disappointing, underscores expected ARWR efficacy edge.
Drug DevelopmentION541 for ALS was discontinued due to lack of efficacy, which has disappointed investors.
Financial PerformanceIonis Pharmaceuticals' stock has been weak, underperforming compared to benchmarks.
---
Ownership Overview
2.96% Insiders
38.03% Mutual Funds
49.60% Other Institutional Investors
9.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $36.37 and its highest was $54.44 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 81 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on May 07, 2024. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.033 by $0.053.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$0.98.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 145,965,380 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.033. Following the earnings report the stock price went down -3.193%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 175M.
---
Ionis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.25 (56.12% Upside)
$58.25 (56.12% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $312.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.78%
12-Months-Change
Fundamentals
Return on Equity
-98.20%
Trailing 12-Months
Asset Growth
-4.20%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
IONS Company Deck
---
IONS Earnings Call
Q1 2024
0:00 / 0:00
---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$58.25
▲(56.12% Upside)
Technical Analysis
Best Analysts Covering IONS
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+15.88%
initiated a buy rating 8 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +15.88% per trade.
---